Skip to Content
Merck

Impact of linker length on the activity of PROTACs.

Molecular bioSystems (2010-10-06)
Kedra Cyrus, Marie Wehenkel, Eun-Young Choi, Hyeong-Jun Han, Hyosung Lee, Hollie Swanson, Kyung-Bo Kim
ABSTRACT

Conventional genetic approaches have provided a powerful tool in the study of proteins. However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes. To overcome these limitations, a small molecule-based novel technology termed "PROteolysis TArgeting ChimeraS (PROTACs)" has been developed, targeting proteins for degradation at the post-translational level. Despite the promising potential of PROTACs to serve as molecular probes of complex signaling pathways, their design has not been generalized for broad application. Here, we present the first generalized approach for PROTAC design by fine-tuning the distance between the two participating partner proteins, the E3 ubiquitin ligase and the target protein. As such, we took a chemical approach to create estrogen receptor (ER)-α targeting PROTACs with varying linker lengths and the loss of the ER in cultured cells was monitored via western blot and fluorometric analyses. We found a significant effect of chain length on PROTAC efficacy, and, in this case, the optimum distance between the E3 recognition motif and the ligand was a 16 atom chain length. The information gathered from this experiment may offer a generalizable PROTAC design strategy to further the expansion of the PROTAC toolbox, opening new possibilities for the broad application of the PROTAC strategy in the study of multiple signaling pathways.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Pomalidomide-pyridine-PEG1-piperazine hydrochloride
Sigma-Aldrich
Thalidomide-O-amido-C8-NH2 trifluoroacetate, ≥95.0%
Sigma-Aldrich
(S,R,S)-AHPC-CO-PEG4-C2-acid, ≥95%
Sigma-Aldrich
2,7-Diazaspiro[3.5]nonane-7-acetic acid, 2-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-, ≥95%
Sigma-Aldrich
Pomalidomide-piperidine-carboxylic acid, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-Me-C5-COOH, ≥95%
Sigma-Aldrich
Pomalidomide-PEG6-butyl CO2H, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-piperazine-pyridine-alkyne-NH2 hydrochloride
Sigma-Aldrich
(S,R,S)-AHPC-acetamido-O-PEG4-C1-acid, ≥95%
Sigma-Aldrich
Propanoic acid, 3-[2-[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]amino]ethoxy]ethoxy]ethoxy]-, ≥95%
Sigma-Aldrich
Pomalidomide-piperazine-piperidine-4-carboxamide hydrochloride
Sigma-Aldrich
Pomalidomide-PEG3-OH, ≥95%
Sigma-Aldrich
3-Pyridinecarboxylic acid, 6-[4-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-1-piperazinyl]-, ≥95%
Sigma-Aldrich
Pomalidomide-PEG4-Azide, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-PEG1-Alkyne, ≥95%
Sigma-Aldrich
Pomalidomide-2,6-diazaspiro[3.3]heptane, ≥95.0%
Sigma-Aldrich
6F,C5-Pomalidomide-4-piperidine-C1-piperazine hydrochloride
Sigma-Aldrich
Pomalidomide-4-piperidine-C1-piperazine hydrochloride
Sigma-Aldrich
1-Piperazinecarboxylic acid, 4-(4-piperidinyl)-, 1,1-dimethylethyl ester, ≥98%
Sigma-Aldrich
4-(Aminoethyl)-1-N-Boc-piperidine, ≥95.0%
Sigma-Aldrich
(S,R,S)-AHPC-benzyl-piperazine hydrochloride
Sigma-Aldrich
C5 Lenalidomide-benzyl-piperazine hydrochloride
Sigma-Aldrich
(S,R,S)-AHPC-alkyne-piperidine hydrochloride
Sigma-Aldrich
(S,R,S)-AHPC-CO-PEG1-C2-acid, ≥95%
Sigma-Aldrich
Pomalidomide-PEG2-C2-azide, ≥95%
Sigma-Aldrich
Pomalidomide-piperazine, ≥ 95.0%
Sigma-Aldrich
(S,R,S)-AHPC-pentanoic-acid, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-pyrimidine-piperazine-PEG1-NH2 hydrochloride
Sigma-Aldrich
Pomalidomide-C3-NH2 hydrochloride, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-PEG2-butyl CO2H, ≥95%